Clinical Implications of Measuring Infliximab Levels and Human Anti-Chimeric Antibodies in Patients with Inflammatory Bowel Disease

被引：1
|
作者：
Rai, Tarun [1 ]
Navaneethan, Udayakumar [1 ]
Dalal, Deepan [1 ]
Lashner, Bret [1 ]
Shen, Bo [1 ]
机构：
[1] Cleveland Clin Fdn, Cleveland, OH 44195 USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2012年 / 107卷
关键词：
D O I：
10.14309/00000434-201210001-01572
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1572
引用
收藏
页码：S634 / S634
页数：1
相关论文
共 50 条
  • [21] The case of Kawasaki disease after rituximab infusion triggered by human anti-chimeric antibodies
    Sato, Masayuki
    Yamada, Masayoshi
    Nakajima, Mika
    Miyama, Yudai
    Kitayama, Hirotsugu
    CEN CASE REPORTS, 2020, 9 (04) : 392 - 394
  • [22] InfliximabDevelopement of human anti-chimeric antibodies: 4 case reports
    Reactions Weekly, 2020, 1787 (1) : 289 - 289
  • [23] The case of Kawasaki disease after rituximab infusion triggered by human anti-chimeric antibodies
    Masayuki Sato
    Masayoshi Yamada
    Mika Nakajima
    Yudai Miyama
    Hirotsugu Kitayama
    CEN Case Reports, 2020, 9 : 392 - 394
  • [24] The effect of infliximab dose escalation in inflammatory bowel disease patients with antibodies to infliximab
    Tun, Gloria S. Z.
    Robinson, Kerry
    Marshall, Laura
    Wright, Alison
    Thompson, Laura
    Wild, Graeme
    Sargur, Ravishankar
    Brooks, Alenka J.
    Hale, Melissa F.
    Chew, Thean S.
    Lobo, Alan J.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 34 (03) : 295 - 301
  • [25] THE EFFECT OF INFLIXIMAB DOSE ESCALATION IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH ANTIBODIES TO INFLIXIMAB
    Tun, Gloria S. Z.
    Marshall, Laura
    Thompson, Laura
    Campbell, Rebecca
    Hale, Melissa F.
    Chew, Thean S.
    Brooks, Alenka J.
    Robinson, Kerry
    Lobo, Alan J.
    GUT, 2019, 68 : A61 - A62
  • [26] Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease
    Pariente, Benjamin
    de Chambrun, Guillaume Pineton
    Krzysiek, Roman
    Desroches, Marine
    Louis, Gauthier
    De Cassan, Chiara
    Baudry, Clotilde
    Gornet, Jean-Marc
    Desreumaux, Pierre
    Emilie, Dominique
    Colombel, Jean-Frederic
    Allez, Matthieu
    INFLAMMATORY BOWEL DISEASES, 2012, 18 (07) : 1199 - 1206
  • [27] A Search for the Best Utilization of Serum Infliximab (IFX) and Antibodies to Infliximab (ATI) Levels in Patients With Inflammatory Bowel Disease
    Sivananthan, Geethan
    Ladd, Antonio Mendoza
    Cohen, Joshua
    Feathers, Alexandra
    Schneider, Judy
    Swaminath, Arun
    Korelitz, Burton
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S492 - S492
  • [28] Human anti-chimeric antibody (HACA) responds to infliximab (Remicade™) in the attract clinical study of patients with active rheumatoid arthritis.
    Wagner, CL
    Schantz, AB
    LaSorda, JA
    DiNoto, DR
    Wang, H
    Marsters, PR
    Harriman, GR
    ARTHRITIS AND RHEUMATISM, 1999, 42 (09): : S83 - S83
  • [29] RAPID POINT-OF-CARE MONITORING OF ANTI-INFLIXIMAB ANTIBODIES AND CLINICAL SCORES IN INFLAMMATORY BOWEL DISEASE PATIENTS
    Facchin, S.
    Buda, A.
    Cardin, R.
    Agbariah, N.
    Zingone, F.
    De Boni, M.
    D'Inca, R.
    Savarino, E.
    DIGESTIVE AND LIVER DISEASE, 2019, 51 : E110 - E111
  • [30] Infliximab trough levels and anti-drug antibodies after induction predict long-term clinical remission in infliximab-treated patients with inflammatory bowel disease
    Bodini, G.
    Del Nero, L.
    Giannini, E. G.
    Tolone, S.
    De Bortoli, N.
    Anjali, J.
    Baldissarro, I.
    Savarino, V.
    Savarino, E.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S408 - S409
12345